Table 2.

Evolution of the number and size of all (target and non-target) non-solid, partially solid, and solid lesions over 60 months in the budesonide and placebo arms

Follow-up (months)	Arm	No. of nodules	Mean maximum nodule diameter in mm (SD)	Median maximum nodule diameter in mm
Non-solid
Baseline	Budesonide	16	5.03 (1.39)	4.65
	Placebo	15	5.26 (0.99)	5.00
60	Budesonide	9	2.61 (2.62)	3.20
	Placebo	11	5.68 (2.81)	5.10
Partially solid
Baseline	Budesonide	31	5.26 (1.52)	4.80
	Placebo	22	5.07 (1.00)	4.90
60	Budesonide	13	4.47 (1.18)	4.25
	Placebo	15	5.17 (1.27)	4.70
Solid
Baseline	Budesonide	114	5.14 (0.96)	4.90
	Placebo	117	4.96 (0.87)	4.70
60	Budesonide	112	5.22 (1.38)	5.10
	Placebo	100	4.97 (1.39)	5.00